


USPTO PATENT FULL-TEXT AND IMAGE DATABASE



(1 of 22)

United States Patent

6,403,618

Fernandez-Pol

June 11, 2002

Agent and method for controlling angiogenesis

Abstract

A metal ion chelating agent such as picolinic acid or derivatives thereof, and methods of using the same. The agents chelate metals in metal containing protein complexes and enzymes required for growth and replication of blood vessel cells. The preparations can be administered systemically or for topical use. The preparations have antineoplastic activity augmented by the antiangiogenic properties.

Inventors: Fernandez-Pol; Jose A. (Chesterfield, MO)

Appl. No.: 677506

Filed: October 2, 2000

Current U.S. Class:

514/354; 514/356; 514/355; 546/320; 546/321

Intern'l Class:

A61K 031/44; C07D 213/80

Field of Search:

514/354,355,356 546/320,321

References Cited [Referenced By]

U.S. Patent Documents

<u>3903285</u>	Sep., 1975	Umezawa et al.	
<u>4044140</u>	Aug., 1977	Sherlock.	
<u>4120762</u>	Oct., 1978	Sviokla.	
<u>4138488</u>	Feb., 1979	Sherlock et al.	424/250.
<u>4139625</u>	Feb., 1979	Sherlock	424/266.

Pico/authorship responsibility PTO-ROTMAN
September 3, 2002

Rotman, Alan L,
Primary Examiner
United States Patent and Trademark Office
Commissioner of Patents and Trademarks
Washington, DC 20231

Reference:

1. Fernandez-Pol, USA patent 6,403,618, June 11, 2002. Agent and method for controlling angiogenesis. Rotman, Alan L, Assistant Examiner: Robinson, Binta.

Subject: AUTHORSHIP RESPONSIBILITY

Dear Examiner Rotman, Alan L.:

By signing this document, I certify that I have not participated sufficiently in the conception and design of this work, the analysis of the data (where applicable) as well as in the writing of the patents, to take public responsibility for it. I cannot warrant that the patents represent valid original work, since I have not even seen a substantial portion of the data presented. I have reviewed the original version of the patent and did not approve its submission without the necessary corrections. Neither this patent nor others with similar content under my authorship should be published without the correction of errors that I indicated in writing to both Novactyl's patent attorneys and to the Board of Directors. Furthermore, I attest that a portion of the data on which the patents are based have never been shown to me by the management. Thus, the management has to produce the data on which this patent is based. The undersign cannot warrant that the patents contain no libelous or unlawful statements, that they do not infringe on the rights of others, or contain material or instructions that might cause harm or injury, particularly in reference to patient treatments which represent cases introduced by the management.

Sincerely,



Jose A. Fernandez-Pol, M.D.
437 Hunters Hill Dr.
Chesterfield, MO 63917-3446

TE: 314-275-7856

P.S.: The management at the time of patent application and prosecution of the patents indicated above were: Michael Douglas, Ph.D., Vice President & Chief Scientific Officer, Mr. Raymond Zipprich, Vice President, Chief Operating Officer & Chief Financial Officer, and Avinash Amin, M.D., Vice President, Clinical Affairs.

Novactyl, Inc
1816 Lackland Hill Parkway, Suite 220
St. Louis, Missouri 63146
Telephone: 314-991-3890
e-mail: zipprich@Novactyl.com